Compare Moderna, Inc. (MRNA) vs United Airlines Holdings Inc (UAL) Price & Performance

Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.

Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.

United Airlines (UAL) trades at $123.76, down 4.48% today, but maintains a bullish technical signal with strong analyst support. The stock shows robust fundamentals, including a P/E of 11.83, net income margin of 5.56%, and three consecutive quarterly EPS beats. Revenue growth is steady, rising to $59.07B in 2025, with cash flow from operations at $8.43B. Recent news highlights CEO Scott Kirby's focus on innovation after merger attempts failed, while industry-wide fuel cost pressures are being managed.

Outlook remains positive with a consensus price target of $167.73, implying 35% upside. Opportunities include strong travel demand and operational efficiency, but risks involve volatile fuel prices, competitive pressures, and execution challenges. Wall Street sentiment is bullish with 66% buy ratings and no sell recommendations, supporting a favorable risk-reward profile for long-term investors.